Overall , 93.6 % ( 218/233 ) of participants experienced treatment-emergent AEs ( TEAEs ) , most commonly nausea ( 56.2 % ; 131/233 ) , nasopharyngitis ( 25.3 % ; 59/233 ) , thirst ( 19.3 % ; 45/233 ) , headache ( 17.2 % ; 40/233 ) , and decreased appetite ( 16.3 % ; 38/233 ) .